Clinical Trial

A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This Phase 1 dose escalation trial will assess the safety and preliminary efficacy of a single dose intravenous infusion of RP-A601 in high-risk adult patients with PKP2-ACM.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-05-22; most recent amendment 2026-04-14.
Status change: Not Yet Recruiting → Recruiting 2023-10-09
Trial Details
NCT Number NCT05885412
Lead Sponsor Rocket Pharmaceuticals Inc.
Conditions PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)
Enrollment 9 participants
Start Date 2023-08-29
Primary Completion 2028-09 (estimated)
Study Completion 2029-09 (estimated)
Updated on ClinicalTrials.gov 2026-04-16